Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
US11999676B2 · kind B2 · utility
0Cited by
3References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 14, 2020 |
| Grant date | Jun 4, 2024 |
| Priority date | — |
| Expiry date | Apr 14, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D333/20
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.